UNSPSC 51321707: Atorvastatin calcium hydrate

This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as atorvastatin calcium (trihydrate), but more generally known as atorvastatin calcium hydrate, which bears US NIH Compound Identifier 656846. European Medicines Agency schedules atorvastatin calcium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG.

Most nations, for tariff purposes, schedule atorvastatin calcium hydrate under HS 29339990. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.O.O.O.[CA+2].

UNSPSC 51321707 Atorvastatin calcium hydrate is a Commodity code representing a single pharmaceutical product line that state and local governments procure primarily through emergency medical services and healthcare benefit programs. Recent solicitations show demand concentrated in two distinct procurement streams: emergency medical services procurement through municipal fire departments and multi-state cooperative purchasing alliances that aggregate pharmaceutical demand across state agencies and participating jurisdictions. The City of Tampa Fire Rescue's April 2026 sealed-bid solicitation for Advanced Life Support Medications (26P00188) exemplifies direct municipal purchasing, though that particular IFB focused on acute-care injectables (Labetalol, Epinephrine, Adenosine, Diltiazem) rather than atorvastatin specifically. Broader multi-state cooperative purchasing dominates the landscape: the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, establishing contracts effective July 1, 2026 through wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. Texas Health and Human Services Commission posted an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling emerging state interest in alternative supply models for pharmacy benefit management.

Recent activity clusters in Texas, Minnesota, and Florida, with the MMCAP cooperative model serving multiple states. Issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas HHS Commission), and multi-state cooperative procurement administrations. The Tampa IFB carried a $40,000 estimated value and included a 5 percent Small Local Business Enterprise (SLBE) sheltered market discount, while the MMCAP RFP (due March 26, 2026, now closed) assessed vendors on price competitiveness (75 percent of evaluation weight), fixed pricing (10 percent), cGMP and DSCSA compliance, and insurance requirements including $5,000,000 general liability and $2,000,000 network security coverage. The Texas RFI remains exploratory, designed to inform future procurement strategy before a formal RFP; no award values or timelines were disclosed. MMCAP requires vendors to maintain relationships with at least two of three authorized wholesalers and comply with a 3 percent administrative fee structure, with contract terms running two years for new vendors and extending through June 30, 2028 for incumbents.